 - Studies could lead to development of next-generation targeted devices to effectively treat chronic pain - Stage I research programs designed to study how electro-modulation communicates to cells - Program objective to d ecipher impacts of alternating electrical fields on cell signaling and generating cellular response - Leveraging the executed agreement EMED and Nazarbayev plan to begin the IDE process with the FDA SCOTTSDALE, Ariz., June 3, 2021 PRNewswire -- Electromedical Technologies, Inc. OTCQB: EMED the Company, a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs. 